Expression of P2X7, P2X4, CD39 and CD73 in non-small cell lung cancer

Expression of P2X7, P2X4, CD39 and CD73 in non-small cell lung cancer - CD39

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021114

Enrollment

200

Registered

2021-11-16

Start date

2020-06-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: The study population consists of all adult patients who have a histologically proven NSCLC, have been treated at the Medical Center of University Freiburg and sufficient tissue biopsies are a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. histologically proven NSCLC 2. Treatment of NSCLC at the Medical Center of University Freiburg between January 2003 and December 2019 3. signed Informed consent form of the Biobank of the Comprehensive Cancer Center Freiburg (CCCF) 4. sufficient tissue availability at the Biobank to perform all planned tests

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
the expression of P2X7, P2X4, CD39 and CD73 in NSCLC-tissue	—

Secondary

Measure	Time frame
to correlate the expression of P2X7, P2X4, CD39 and CD73 with the TNM-stadium, the overall survival and the relapse-free survival / interval.	—

Countries

Germany

Contacts

Public ContactKonstantinos Grapatsas

Universitätsklinikum Freiburg Klinik für Thoraxchirurgie

konstantinos.grapatsas@uniklinik-freiburg.de+49 761 27024720

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026